Scope The Current South-east Asia T2dm Market Contains Novel Products, Including Jardiance, A Sglt-2 Inhibitor; Victoza, A Glp-1 Receptor Agonist; And Januvia, A Dpp-4 Inhibitor.

In recent years targeting the pathway controlling vessel growth or angiogenesis has been promising. laser is sometimes applied before anti-VEGF injections, sometimes on the same day or a few days after an anti-VEGF injection, and sometimes only when DBE fails to improve adequately after six months of anti-VEGF therapy. In the clinic, diagnostic devices that use A may improve the detection of subtle changes in retinal tissue and blood vessels. The lei is conducting and supporting research that seeks better ways to detect, treat, and prevent vision loss in people with diabetes. Diagnosis of retinopathy is generally made by an eye specialist called an ophthalmologist. Two kinds of diabetic retinopathy have the potential to diminish vision: In non proliferative retinopathy, blood vessels in the retina deteriorate. may also lose their ability to transport blood. People with very high blood pressure and swelling of the optic nerve require emergency treatment in a hospital. After light passes through the cornea, it travels through a space called the anterior chamber which is filled with a protective fluid called the aqueous humour, through the pupil which is a hole in the iris, the coloured part of the eye, and then through a lens that performs more focusing. In advanced diabetic retinopathy the signals sent by the retina for nourishment trigger the growth of new blood vessels.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease. Scope The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor. What are the competitive advantages of the existing novel drugs? With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies. Which classes of novel drugs are most prominent within the pipeline? Is there strong potential for the pipeline to address unmet needs within the T2DM market? Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%. How do failure rates vary by product stage of development, molecule type, and mechanism of action?

For the original version including any supplementary images or video, visit